ATLANTA, Dec. 15, 2025 /PRNewswire/ — iCHASE, a global leader in AI-driven agricultural biosecurity solutions, will showcase the world’s first AI-powered bird deterrent system with full data tracking capabilities at the 2026 International Production & Processing Expo (IPPE). As avian influenza continues to impact livestock production, iCHASE demonstrates how its AI Bird Repeller delivers measurable financial returns and contamination reduction across commercial operations.

Solving a Critical Biosecurity Challenge

Wild birds remain the leading transmission vector of avian influenza, contaminating feed areas and causing substantial productivity losses. During the recent H5N1 wave, dairy farms reported up to 20% milk yield reduction, while poultry operations experienced the highest mortality rates since 2022.

AI Bird Repeller: Verified ROI and Data-Driven Biosecurity

The AI Bird Repeller uses computer vision to detect wild birds and automatically deploys adaptive deterrent strategies that prevent habituation. The integrated platform provides comprehensive data logging, enabling producers to visualize activity patterns, quantify risk exposure, and track performance over time.

U.S. farms document measurable financial impact—generating $20,000–$35,000 in annual savings for typical dairy operations with payback within 7-12 months through reduced feed loss, lower contamination, and improved operational resilience.

The system supports remote configuration, allowing operators and integrators to adjust settings and optimize performance without on-site visits.

North American Market Expansion

Demand for iCHASE biosecurity technologies continues growing as producers seek reliable, measurable solutions. iCHASE has expanded its regional presence to ensure timely planning support, deployment services, and technical assistance. Organizations interested in becoming regional distributors or integrators are encouraged to contact the company.

Live Demonstrations at IPPE 2026

iCHASE will offer live demonstrations and complimentary on-site evaluation consultations to help operations assess ROI and contamination-reduction benefits.

Visit Booth B9047

About iCHASE

iCHASE develops advanced AI-powered solutions for livestock production, including the AI Bird Repeller for biosecurity management and InsightScale for precision broiler monitoring. Serving customers in 20+ countries worldwide, iCHASE delivers measurable improvements in efficiency, safety, and disease prevention.

Learn more at www.ichase.io

The company is revolutionizing regenerative healthcare through innovation, clinical alignment, and GMP-grade excellence across Southeast Asia

SAN ANTONIO, Dec. 15, 2025 /PRNewswire/ — Frost & Sullivan is pleased to announce that MEDEZE Group Public Company Limited (MEDEZE) has been honored with the 2025 Southeast Asia Company of the Year Recognition in the stem cell banking and regenerative medicine industry for its outstanding achievements in innovation, regulatory leadership, and clinical alignment. This recognition highlights MEDEZE’s leadership in advancing the next generation of personalized healthcare solutions while maintaining the highest global standards in safety, technology, and compliance.

This recognition highlights MEDEZE’s leadership in advancing the next generation of personalized healthcare solutions while maintaining the highest global standards in safety, technology, and compliance.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. MEDEZE excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with precision and scale. “MEDEZE is redefining stem cell banking in Southeast Asia through full-spectrum, clinically aligned solutions, leveraging innovation, regulatory leadership, and GMP-grade infrastructure to lead the transition from cell preservation to personalized medical application,” said Unmesh Lal, Vice President, Healthcare & Life Sciences at Frost & Sullivan.

Driven by a long-term strategy focused on innovation, clinical readiness, and international expansion, MEDEZE has built one of the region’s most comprehensive and technologically advanced cell banking ecosystems. Its vertically integrated model—spanning biological material collection, diagnostics, cell processing, storage, expansion, and clinical application—ensures consistent quality, regulatory compliance, and scalability across Southeast Asia.

Innovation is central to MEDEZE’s success. Proprietary technologies, such as the AutoXpress System for fully automated cord blood processing and the Chibuya Robotic Stem Cell Culture System (the world’s first full-room cleanroom automation), enable therapeutic-grade manufacturing at scale. The company’s AI-powered Hair Follicle Restoration platform and exclusive NK cell diagnostic technologies from Japan demonstrate its ability to extend cell applications into clinical and aesthetic care.

MEDEZE’s commitment to international accreditation and operational excellence strengthens its leadership in regenerative medicine. It is the only Thai stem cell bank accredited by the US-based Association for the Advancement of Blood & Biotherapies (AABB) and holds ISO 9001 and ISO 22716 certifications. These accreditations reinforce the company’s compliance with the highest safety and quality standards across both therapeutic and wellness applications.

Supported by a network of over 260 hospital partners, including leading institutions such as Samitivej Hospital Group and Bangkok Hospital, MEDEZE plays a central role in Thailand’s ADMP Sandbox clinical program. Through ongoing trials in osteoarthritis, degenerative disc disease, skin rejuvenation, colorectal cancer, and immune enhancement, MEDEZE is positioned to become one of the first private companies in Southeast Asia to commercialize licensed cell therapies by 2026.

Frost & Sullivan commends MEDEZE for setting a new benchmark in competitive strategy, innovation, and market responsiveness. Its integrated operational model, financial strength, and commitment to sustainable growth exemplify leadership in biotechnology and position it at the forefront of Southeast Asia’s transition toward licensed regenerative therapies.

Each year, Frost & Sullivan presents the Company of the Year Recognition to an organization that demonstrates outstanding strategy development and execution, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The recognition celebrates forward-thinking companies that are redefining their industries through innovation and growth excellence.

Frost & Sullivan Best Practices Recognition
Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.
Contact us: Start the discussion.

Contact:
Tarini Singh
E: Tarini.Singh@frost.com 

HANGZHOU, China, Dec. 15, 2025 /PRNewswire/ — China’s top international privately-owned enterprises represent a distinct and increasingly influential group within the global economy – companies whose international presence is defined less by export volume and more by embedded global operations, innovation capability and long-term responsibility.

Who, then, are these firms? The answer emerges from the newly released 2025 China’s Top 100 Most International Privately-Owned Enterprises, published by the Center for Chinese Multinationals (CCM) at Zhejiang University International Business School (ZIBS), in collaboration with the Cambridge Centre for Chinese Management and the Zheshang Institute.

Now in its fifth consecutive year, the ranking has evolved from a measurement exercise into a structured portrait of a new generation of globally active private enterprises. It assesses companies across four core dimensions – scale of internationalization, international organizational structure, international innovation, and international influence. Rather than asking how much these firms export, the 2025 edition asks how they operate globally – and what distinguishes them as global business actors.

A Structural Shift: Globalization Beyond Exports

The Top 100 companies generated a combined RMB 3.98 trillion (USD ~560 billion) in overseas revenue, accounting for 33.3% of their total revenue, with average overseas revenue reaching RMB 39.78 billion per company. Collectively, they form a group for which international markets are no longer peripheral, but structurally embedded in core business operations. All ranked firms have established overseas subsidiaries, operating across an average of 18 countries and regions.

Overseas footprints are most concentrated in East Asia (79 companies), North America (64), Southeast Asia (63) and Europe (58) – a pattern that reflects not opportunistic expansion, but deliberate global positioning.

Together, these figures suggest that Chinese private enterprises are moving decisively beyond cross-border trade. Increasingly, they are embedding themselves in local markets – through regional headquarters, localized manufacturing, service networks and, in some cases, overseas R&D – signaling a shift from transactional globalization to long-term market integration.

Manufacturing as the Backbone of Global Reach

Manufacturing remains the anchor of this global expansion. Eighty-four of the Top 100 companies come from manufacturing industries, underscoring China’s enduring strengths as a global manufacturing powerhouse.

At a more granular level, three sectors stand out: computer, communications and electronic equipment manufacturing (25 companies); electrical machinery and equipment (20); and non-ferrous metal smelting and rolling (8). Their prominence highlights the growing international competitiveness of China’s private manufacturers in advanced equipment, electronics and high-value industrial systems – areas where success depends on engineering depth, supply-chain coordination and sustained innovation, rather than scale alone.

Regional Clusters Highlight the Yangtze River Delta’s Leadership

The Top 100 enterprises span 21 provinces, autonomous regions and municipalities across China. Zhejiang and Guangdong lead with 22 companies each, followed by Jiangsu and Shandong (8 each), and Beijing and Shanghai (6 each).

This clustering effect is particularly pronounced in the Yangtze River Delta, which has emerged as the most important domestic hub supporting the internationalization of private enterprises – demonstrating how dense industrial ecosystems, innovation infrastructure and global connectivity at home continue to shape firms’ ability to compete abroad.

Innovation as a Prerequisite, Not an Option

Behind global expansion lies sustained investment in innovation. In 2024, the Top 100 companies recorded total R&D investment of RMB 456 billion, averaging RMB 4.6 billion per firm, while collectively holding 60,935 patents.

These figures align with broader national trends: private enterprises now account for more than 50% of China’s total R&D expenditure and over 70% of technological innovation outcomes. Among the most internationalized firms, innovation is no longer a supporting function – it is a foundational condition for sustaining global competitiveness, particularly in technology- and capital-intensive industries.

From Market Presence to Global Influence

The most subtle, yet consequential, transformation captured by the ranking lies in influence. Internationalization is no longer measured solely by market access, but increasingly by visibility, credibility and responsibility.

The Top 100 companies recorded more than 816 million global online searches over the past year, reflecting the rising visibility of Chinese brands among global consumers. At the same time, their average ESG score of 80.65 points to a deeper integration of environmental, social and governance considerations into global operations.

Leading firms are treating ESG not as a reporting obligation, but as a source of competitive advantage – investing in green manufacturing overseas, advancing supply-chain decarbonization and building long-term partnerships with local communities. In this sense, the most internationalized private enterprises are distinguished not only by where they operate, but by how they are perceived and accepted in global markets.

Defining a New Profile of Global Enterprise

Taken together, the 2025 China’s Top 100 Most International Privately-Owned Enterprises answers a central question: who are China’s most international private companies today? They are no longer defined primarily as exporters or cost-driven manufacturers. They are becoming system builders, innovators and responsible global participants.

This evolving profile reflects a broader transformation in global business itself, offering valuable insights into how emerging-market enterprises can build sustainable global presence – not merely through scale, but through structure, innovation and legitimacy – in an increasingly complex international environment.

About the Center for Chinese Multinationals (CCM):

Established in Nov. 2022, the Center for Chinese Multinationals (CCM) at Zhejiang University International Business School (ZIBS) aims at becoming a leading research center on the internationalization of Chinese private enterprises and works to strengthen the bridge between government, academia and industry through innovative academic initiatives and through continuous contact with business leaders, regulators and entrepreneurs. Learn more about the center: Sally Shen, sallyshen@zju.edu.cn; Hengyu Lu, hengyulu@intl.zju.edu.cn.